Therapeutic Asset Ratings
266 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tazemetostat
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(51)
Vinorelbine
Peripheral T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(51)
Catequentinib
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(50)
cd7.car/28zeta car t cells
T-Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(50)
Omacetaxine
Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2/3
CCC
(50)
Docetaxel
Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(48)
Mecapegfilgrastim
Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(48)
Orelabrutinib
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(48)
Zeprumetostat
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
CCC
(48)
Baff-R Car-T
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Baff-R Car-T
Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Baff-R Car-T
Waldenstrom Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Bcma-Cart Cells
Plasmacytoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Bcma-Cart Cells
Refractory Malignant Neoplasm
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Bcma-Cart Cells
R2-ISS-IV /MPSS-IV
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
C-Car088
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
cd7.car/28zeta car t cells
Relapsed/Refractory Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Immunoglobulin G1-kappa, anti-[Homo sapiens CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1)], humanized monoclonal antibody
T-ALL
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Promethazine
FL
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Promethazine
MZL
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
Promethazine
WM
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CCC
(48)
5-azacytidine
FLT3 Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(47)
Baff-R Car-T
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(47)
Baff-R Car-T
Diffuse Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(47)
Baff-R Car-T
Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(47)
Showing 151 to 175 of 266 assets
Previous
Page 7 of 11
Next